UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Annals of oncology, 2022-02, Vol.33 (2), p.169-180

2022

Volltextzugriff (PDF)

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

Annals of the rheumatic diseases, 2006-06, Vol.65 (6), p.753-759

2006

Volltextzugriff (PDF)

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

Cancer Immunology, Immunotherapy, 2022-12, Vol.71 (12), p.2985-2998

2022

Volltextzugriff (PDF)

Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

Annals of oncology, 2018-10, Vol.29, p.viii712-viii712

2018

Volltextzugriff (PDF)

Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis

Clinical and experimental rheumatology, 2007-11, Vol.25 (6), p.838

2007

Volltextzugriff (PDF)

Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis

Journal of rheumatology, 2005-05, Vol.32 (5), p.811

2005

Volltextzugriff (PDF)

715MO Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study

Annals of oncology, 2024-09, Vol.35, p.S548-S548

2024

Volltextzugriff (PDF)

716MO Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer

Annals of oncology, 2024-09, Vol.35, p.S548-S549

2024

Volltextzugriff (PDF)

Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate

Rheumatology (Oxford, England), 2004-06, Vol.43 (6), p.712-718

2004

Volltextzugriff (PDF)

LBA16Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

Annals of oncology, 2020-09, Vol.31, p.S887-S887

2020

Volltextzugriff (PDF)

1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC

Annals of oncology, 2020-09, Vol.31, p.S891-S892

2020

Volltextzugriff (PDF)

P75.03 KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S573-S573

2021

Volltextzugriff (PDF)

Cardiac manifestations of the antiphospholipid syndrome

The American heart journal, 1992-11, Vol.124 (5), p.1331-1338

1992

Volltextzugriff (PDF)

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

Journal of rheumatology, 2003-12, Vol.30 (12), p.2563

2003

Volltextzugriff (PDF)

Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma

Annals of oncology, 2016-10, Vol.27, p.vi365-vi365

2016

Volltextzugriff (PDF)

Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome

The American journal of medicine, 1989-04, Vol.86 (1), p.407-412

1989

Volltextzugriff (PDF)

Clonal expansion is a characteristic feature of the B-cell repertoire of patients with rheumatoid arthritis

Arthritis research, 1999-12, Vol.2 (Suppl 1), p.50-58, Article 50

1999

Volltextzugriff (PDF)

Reversible monocular blindness complicating Churg-Strauss syndrome

Journal of rheumatology, 1994-02, Vol.21 (2), p.363

1994

Volltextzugriff (PDF)

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

Clinical therapeutics, 2003-06, Vol.25 (6), p.1700-1721

2003

Volltextzugriff (PDF)

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Arthritis and rheumatism, 2004-05, Vol.50 (5), p.1400-1411

2004

Volltextzugriff (PDF)

Human immunodeficiency virus infection of helper T cell clones: early proliferative defects despite intact antigen-specific recognition and interleukin 4 secretion

The Journal of clinical investigation, 1989-06, Vol.83 (6), p.1843-1848

1989

Volltextzugriff (PDF)

Septic subdeltoid bursitis

Seminars in arthritis and rheumatism, 1992-08, Vol.22 (1), p.25-29

1992

Volltextzugriff (PDF)

CDR3 Length Restriction of T-Cell Receptor β Chains in CD8+ T-Cells of Rheumatoid Arthritis Patients

Annals of the New York Academy of Sciences, 1995-07, Vol.756 (1), p.179-182

1995

Volltextzugriff (PDF)

Biochemical basis of synergy between antigen and T helper (Th) cell-mediated activation of resting human B cells

The Journal of clinical investigation, 1989-11, Vol.84 (5), p.1410-1417

1989

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(45)
magazinearticle
(1)

Sprache

Englisch
(46)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(30)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Biological And Medical Sciences
(22)
Female
(18)
Medical Sciences
(18)
Adult
(16)
Aged
(16)
Male
(15)
Middle Aged
(15)
Rheumatology
(14)
Immunology
(8)
Adalimumab
(7)
Aged, 80 And Over
(7)
Antibodies, Monoclonal, Humanized
(7)
Diseases Of The Osteoarticular System
(7)
Inflammatory Joint Diseases
(7)
Rheumatoid Arthritis
(7)
Arthritis, Rheumatoid - Drug Therapy
(6)
B-Lymphocytes - Immunology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies

Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid–inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis

Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis

715MO Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study

716MO Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer

Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate

LBA16Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors

1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC

1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC

P75.03 KEYNOTE-U01: A Phase 2 Umbrella Study of Investigational Agents Plus Pembrolizumab-Based Therapy for Advanced NSCLC

Cardiac manifestations of the antiphospholipid syndrome

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)

Phase 1b/2, open-label, multicenter, dose escalation and expansion trial of intratumoral SD 101 in combination with pembrolizumab in patients with metastatic melanoma

Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome

Clonal expansion is a characteristic feature of the B-cell repertoire of patients with rheumatoid arthritis

Reversible monocular blindness complicating Churg-Strauss syndrome

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial

Human immunodeficiency virus infection of helper T cell clones: early proliferative defects despite intact antigen-specific recognition and interleukin 4 secretion

Septic subdeltoid bursitis

CDR3 Length Restriction of T-Cell Receptor β Chains in CD8+ T-Cells of Rheumatoid Arthritis Patients

Biochemical basis of synergy between antigen and T helper (Th) cell-mediated activation of resting human B cells

Suchergebnisse filtern